Skip to main content

Efficacy and safety of microfragmented autologous adipose tissue transplantation for perianal fistulas in Crohn's disease (ATTIC): a phase 3 multicenter randomized controlled trial

In brief

Microfragmented fat raised Crohn's fistula remission to 58%, versus 18% with surgery alone

At 24 weeks, MRI-confirmed remission occurred in 19 of 33 patients given microfragmented fat after fistula surgery, compared with 6 of 33 who had surgery with saline injection. Surgery alone also improved symptoms, and adverse events did not differ significantly between groups. The trial supports added benefit, but longer-term durability remains unknown.

Journal
Journal of Crohn's & colitis (Q1)
Published
7 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Silvio Laureti, Luigi Sofo, Francesco Colombo, Gaetano Luglio, Stefano Scaringi, Alberta Cappelli, et al.
PMID
43050612
DOI
10.1093/ecco-jcc/jjag174

Why clinicians should know about it

  • Picked for Gastroenterology (paper of the day, 19 November 2026): Phase III randomized trial of refractory Crohn's perianal fistula treatment
  • Picked for Surgery (paper of the day, 19 November 2026): Randomized trial of operative treatment for complex Crohn's fistulas

Abstract

BACKGROUND AND AIMS: Complex perianal fistulas in Crohn's disease are often refractory to the recommended combination of surgery and biological drug therapy. We investigated the efficacy and safety of minimally manipulated, microfragmented, autologous adipose tissue ("MFat"), after surgical debridement of the fistula, in patients with Crohn's disease in whom standard treatments had failed. METHODS: This double-blind, randomized controlled trial enrolled 80 adults who all underwent cone-like partial fistulectomy of a complex fistula (one inner orifice and up to three external openings) followed by either MFat injection or suture of the inner orifice and saline injection. MFat was prepared from lipoaspirates using Lipogems medical devices immediately before fistulectomy and transplanted around the inner orifice and along the residual tracts immediately after fistulectomy. The primary efficacy outcome was combined (clinicoradiological) remission at 24 weeks in the per-protocol populations. Safety was assessed in the all-patients-treated populations. RESULTS: After randomization, 37 patients in each group were treated and 33 patients each were assessed. Combined remission occurred in 19 patients (57.6%) of the intervention group and six control patients (18.2%) (risk ratio 3.17; 95% CI, 1.45-6.91; P = .004; number needed to treat, 3). Clinical remission was found in 26 (78.8%) and 18 (54.5%) patients, respectively (P = .044), while clinical indices improved in both groups. Seven adverse events were reported, without significant differences between groups in safety endpoints. CONCLUSIONS: Partial fistulectomy alone led to substantial clinical improvement, but the addition of MFat significantly increased the likelihood of achieving MRI-confirmed healing. Registered at ClinicalTrials.gov (NCT05594862).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.